What it is
Orforglipron is a GLP-1 receptor agonist taken by mouth as a pill rather than injected.
GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases when you eat. An agonist is something that copies a hormone and switches on the same receptors it would.
It increases the release of insulin from the pancreas in two ways: by increasing the number of beta cells, which are the cells that produce insulin, and by reducing the release of glucagon, a hormone that raises blood sugar levels.
It is primarily a weight loss drug. It works by slowing the movement of food from the stomach into the small intestine, which increases satiety — the feeling of having eaten enough — reduces food intake, and makes energy use more efficient.
Because it is a pill, there is no mixing and no injecting. You will need a pill splitter for the first two weeks, since the schedule starts at a quarter of a pill.
One practical advantage: there are no water-intake restrictions around dosing, unlike the previous oral GLP formulation.
Orforglipron is an orally bioavailable, non-peptidic GLP-1 receptor agonist — the oral route is the point of difference from the injectable GLP class.
Mechanism: increases insulin release from the pancreas by increasing beta cell volume, and reduces glucagon release. Primarily positioned as a weight loss agent, acting by slowing gastric transit into the small intestine, producing increased satiety, reduced food intake, and more efficient energy expenditure.
Dosing is once daily, 6 mg per pill, titrated from a quarter pill (1.5 mg) to six pills (36 mg) across 36 weeks. A pill splitter is required for the first two weeks.
No dosing-related water intake restrictions apply, in contrast to the previous oral GLP formulation.
No benefit list, side-effect list, or contraindication list has been documented for it. Nothing is asserted on those fronts below.
What it does
Insulin and blood sugar: it increases the release of insulin from the pancreas, both by increasing the number of insulin-producing beta cells and by reducing the release of glucagon, the hormone that raises blood sugar.
Appetite and digestion: it slows the movement of food from the stomach into the small intestine. That produces a longer-lasting feeling of fullness and reduces how much you eat.
Energy: the result is described as more efficient energy expenditure.
Beyond these points, no trial outcome figures or list of secondary effects are available here.
Endocrine: increased insulin secretion via increased beta cell volume; reduced glucagon release.
Gastric: slowed gastric transit into the small intestine, producing increased satiety and reduced food intake.
Energetic: more efficient energy expenditure.
No trial outcome data, comparative efficacy figures, or secondary effect list are available here for orforglipron.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Taken as a pill — no mixing, no injections.Human trials
- Increased satiety, meaning a longer-lasting feeling of having eaten enough.Limited human data
- Reduced food intake.Limited human data
- More efficient energy expenditure.Anecdotal
- Increases insulin release from the pancreas by increasing the number of insulin-producing beta cells.Animal or lab only
- Reduces the release of glucagon, the hormone that raises blood sugar.Limited human data
- No water intake restrictions around dosing, unlike the previous oral GLP formulation.Human trials
- Can be taken at any time of day, and does not require fasting.Human trials
- Orally bioavailable — no reconstitution or injection.Human trials
- Increased satiety and reduced food intake via slowed gastric transit.Limited human data
- More efficient energy expenditure.Anecdotal
- Increased insulin secretion through increased beta cell volume.Animal or lab only
- Reduced glucagon release.Limited human data
- No dosing-related water intake restrictions, unlike the prior oral GLP formulation.Human trials
- Timing-agnostic and does not require a fasted state.Human trials
Reconstitution and dosing
Orforglipron is taken as a pill, once a day. Each whole pill is 6 mg.
The schedule climbs across 36 weeks:
- Week 1: a quarter of a pill (1.5 mg)
- Week 2: half a pill (3 mg)
- Weeks 3–6: 1 pill (6 mg)
- Weeks 7–10: 2 pills (12 mg)
- Weeks 11–14: 3 pills (18 mg)
- Weeks 15–18: 4 pills (24 mg)
- Weeks 19–22: 5 pills (30 mg)
- Weeks 24–36: 6 pills (36 mg)
You will need a pill splitter for the first two weeks to dose the quarter and the half accurately.
After 36 weeks, take a break of 18 to 36 weeks before starting a new cycle.
You may take it at any time of day, and you do not have to be fasted. There are no water intake restrictions around dosing.
Note: the schedule skips week 23 — it goes from weeks 19–22 straight to weeks 24–36.
Oral, once daily, 6 mg per pill. Titration across 36 weeks: 1.5 mg (quarter pill) week 1; 3 mg (half pill) week 2; 6 mg weeks 3–6; 12 mg weeks 7–10; 18 mg weeks 11–14; 24 mg weeks 15–18; 30 mg weeks 19–22; 36 mg weeks 24–36.
The week numbering skips week 23; the ranges above are shown uncorrected.
A pill splitter is required for the first two weeks.
Cycle: 18–36 weeks on, then an 18–36 week washout before the next cycle.
Any time of day, fasting not required, and no water-intake restrictions — the last point being the explicit contrast with the previous oral GLP formulation.
Oral pills — 6 mg per pill (a pill splitter is needed for weeks 1 and 2)
Cycle: 18–36 week cycle followed by an 18–36 week washout · Frequency: Once per day; any time of day; fasting not required; no water intake restrictions
| When | Dose | How often |
|---|---|---|
| Week 1 | 1/4 of a pill (1.5 mg) | once per day |
| Week 2 | 1/2 of a pill (3 mg) | once per day |
| Weeks 3–6 | 1 pill (6 mg) | once per day |
| Weeks 7–10 | 2 pills (12 mg) | once per day |
| Weeks 11–14 | 3 pills (18 mg) | once per day |
| Weeks 15–18 | 4 pills (24 mg) | once per day |
| Weeks 19–22 | 5 pills (30 mg) | once per day |
| Weeks 24–36 (the numbering skips week 23) | 6 pills (36 mg) | once per day |
Who should avoid it
- No contraindications list has been documented for Orforglipron. That is a gap in the available information, not a statement that there are none — every other GLP page on this site carries one, and most of those lists are long.
- Talk to a doctor before starting any GLP compound.
- No contraindication list has been documented. Treat that as missing documentation rather than as a clean profile; the sibling GLP pages carry substantial exclusion lists, several of them class-wide (medullary thyroid carcinoma and MEN 2 history, pregnancy, pancreatitis, severe GI disease).
Side effects
- No side effects have been documented for Orforglipron. That is a gap in the available information rather than a statement that none occur.
- No side-effect list has been documented. Absence of documentation, not documented absence.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
- Do not combine with injectable GLP-1 agonists
No stacks are suggested for Orforglipron. This entry is a caution rather than a recommendation: other pages on the site warn against running two GLP compounds together, because they compete for the same receptors.
No stacks are documented for Orforglipron. Listed here as a caution: the GLP2-T entry grades other GLP peptides as a severe interaction on receptor redundancy and desensitisation grounds, and the Survodutide and Mazdutide entries both direct users to rotate GLP compounds between cycles rather than combine them. That guidance applies to an oral GLP-1 agonist as much as an injectable one.
Dosing figures have been reviewed and units are recomputed from the stated protocol.